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SHORT COMMUNICATION
Anxiety in women 'at risk' of developing breast cancer
K Thirlaway1, L Fallowfield', H Nunnerley2 and T Powles3
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Summary Do family history clinics offering counselling, surveillance and preventative programmes alleviate or
exacerbate anxiety in women at a high risk of developing breast cancer? In this study risk perceptions and
anxiety of 99 'at risk' women participating in the Tamoxifen Prevention Trial were compared with those of 87
'at risk' women not attending any specialist clinic who were recruited from the National Breast Screening
Programme (NBSP). Most anxiety was found in NBSP women with a family history. Women attending the
family history clinic and participating in the trial had anxiety scores comparable with 86 women recruited from
the NBSP who did not have a family history. We conclude that such specialist clinics do not see a selected
group of the most anxious 'at risk' women nor does participation in tamoxifen prevention programmes appear
to increase anxiety.
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Awareness of the hereditary nature of breast cancer is
increasing among those women who have relatives with
breast cancer. Howe (1981) reported that 76% of 95
American women with a family history of breast cancer did
not consider themselves to be at higher risk than the general
population. Ten years later, the message seemed to have
reached more American women: Kash et al. (1992) found
only 24% of 'at risk' women felt that their risk was either low
or nil. The picture is similar among British women. Evans et
al. (1993) reported that 29% of 155 women attending a breast
cancer family history clinic underestimated their personal
risk.
Although there have been two American studies reporting
high levels of anxiety in women with a family history of
breast cancer attending a breast cancer family history clinic
(Kash et al., 1992; Lerman and Croyle, 1994), it is not known
how anxiety-provoking the recognition of personal risk status
is for British women. Furthermore, there are no published
data concerning the anxiety of women who know that they
have a family history placing them at high risk but do not
attend specialist clinics. This raises the question as to whether
or not anxiety is prevalent throughout the entire population
of 'at risk' women or if family history clinics see a self-
selected group of the most anxious. It is also possible that
attending a family history clinic exacerbates or alleviates
anxiety. Furthermore, there may well be differences in the
understanding of risk in women attending compared with
those not attending a specialist clinic.
Currently British women with a family history of breast
cancer who are attending family history clinics are being
offered the opportunity to participate in a chemoprevention
trial. Following genetic counselling about breast cancer risk
and the nature of the trial, consenting women are randomised
to either tamoxifen or a placebo for 5 years. We report a
study comparing anxiety in 99 women participating in the
tamoxifen prevention trial with that found in 87 women with
a family history who are not attending a specialist clinic and
86 women without a reported family history. The non-trial
women were all recruited from the National Breast Screening
Programme (NBSP). Consequently, all the women in the
study have undergone the same potentially anxiety-provoking
experience of mammography.
Method
Subjects
Tamoxifen trial participants A total of 550 women are
currently participating in the psychosocial arm of the
chemoprevention trial of tamoxifen in women at high
genetic risk of developing breast cancer. In the psychosocial
study the impact that long-term tamoxifen has on quality of
life variables is being assessed. One hundred of the trial
participants recruited from the Royal Marsden Hospital
family history clinic were randomly selected for the
comparative study being reported here.
Women were referred to the Royal Marsden by their
general practitioners and had therefore received some
information about risk before their visit. At the clinic they
underwent clinical examination and mammography, followed
by genetic counselling. Eligible women with a greater than 4-
fold risk were told about the chemoprevention trial. All this
information was repeated on a detailed information sheet
that they were required to read before giving informed
consent to joining the prevention trial.
National Breast Screening Programme participants A total
of 131 women with a family history of breast cancer and 126
women without such a history were recruited from women
attending for routine screening as part of the National Breast
Screening Programme in south-east London. These women
received no genetic counselling before recruitment. The
women in all groups were aged 50 years or more.
Women were classified using the Registrar General
Classification System according to their occupation: I,
professional; II, semi professional; III, skilled; IV, unskilled
and V, not classifiable. The final class V included housewives,
students, voluntary counsellors and others with an occupa-
tion that did not fit the first four categories. Women
participating in the prevention trial were more likely to be
from groups I and II than women from the National Breast
Screening Programme (chi-square test = 19.9, P<0.0001), but
as the majority of women were unclassifiable by occupation
(V) these data are an unreliable means of establishing the
social class of the groups.
Assessment measures
All subjects were given the Spielberger trait anxiety
inventory, a standardised clinical tool for measuring anxiety
(Spielberger et al., 1983), and a questionnaire examining
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women's understanding of: perception of risk in the general
population; causality of breast lumps; the relationship
between age and breast cancer risk; and other demographic
and behavioural variables associated with breast cancer risk
(Fallowfield et al., 1990). Women were asked to indicate
whether they believed the general population risk to be 1 in
100, 1 in 55 or 1 in 12. These questionnaires had been used in
a previously reported study of breast cancer screening
(Fallowfield et al., 1990).
Trait anxiety was used as a measure of anxiety for two
reasons. Firstly, having an increased risk of developing breast
cancer is a permanent condition so any negative effect on
anxiety would be expected to be consistent and long-term.
Secondly, as women in the study returned their question-
naires by post, ensuring they completed them at the same
time was impossible, rendering a measure of state anxiety
(how you feel right now) inappropriate.
Procedure
Questionnaires were given to all women who consented to
join the psychosocial arm of the tamoxifen prevention trial,
at trial entry after mammography. They had been informed
that the purpose of the psychosocial study was to assess the
effect of tamoxifen on anxiety and other quality of life
variables. Prepaid envelopes were provided for the return of
the questionnaires.
Women at the national breast screening clinic were
recruited into the study following their mammogram. They
were given both questionnaires and asked to return them in
prepaid envelopes. They were informed that the study aimed
to monitor the impact ofthe screening programme on anxiety.
Family history status was confirmed by the radiologist who
routinely asked all women a number ofsociodemographic and
clinical questions including family history.
The entry criteria for women aged 50 or more to join the
tamoxifen prevention trial were a mother or sister who has
had breast cancer or two close relatives who have had breast
cancer. The entry criterion for participation in the
psychological study for women attending for routine screen-
ing mammography was at least one close maternal relative
with breast cancer. Radiologists at the screening clinic did
not have time to research family history in great detail.
Therefore, it is possible that some women with a family
history recruited from the NBSP would not have had
sufficiently high risks to make them eligible for the
tamoxifen prevention trial.
Trial participants and women from the screening
programme were all given the questionnaires to take home
and complete on the same day that they had their
mammogram so time between mammography and comple-
tion of the questionnaires was similar for both.
Analysis
The data were analysed using the SPSS/PC statistical
package. Initially, a stepwise regression analysis was carried
out to identify any variables related to anxiety. The potential
variables entered into the regression analysis were: overall
knowledge score, understanding of general population risk
for breast cancer, understanding of hereditary nature of
breast cancer, occupation, age, clinic attended, family history
status.
The Mantel-Haenszel test for linear association was used
to examine the relationship between occupation, recruitment
centre and the two relevant factors generated from the
regression analysis. A two-way analysis of variance:
experimental group (tamoxifen trial participants/NBSP with
history/NBSP without history) x factors generated from the
regression analysis, was used to analyse anxiety scores. One-
way analysis of variance was used to examine any significant
interactions further. This is a conservative process that biases
against any significant findings. t-Tests were used to compare
group means.
Results
Compliance
Tamoxifen trial participants A total of 88.2% of women
participating in the psychosocial arm of the tamoxifen trial
returned their questionnaires. One hundred of these were
randomly selected for the comparative study reported here.
One woman had failed to complete the questionnaires so data
from 99 women were available for analysis.
National Breast Screening Programmeparticipants Question-
naires were given to 131 women with and 126 without a
family history. A total of 105 (80%) of those with a history
and 96 (76%) of those without a history returned the
questionnaires. Owing to failure to complete the question-
naires correctly, returning them unanswered or only
completing one questionnaire, data from 87 women with a
family history and 86 without such a history were available
for analysis.
Factors associated with anxiety
Regression analysis showed that two variables, understanding
of breast cancer risk in the general population and
understanding of the hereditary nature of breast cancer,
explained 3% (adjusted R2=0.03) of the total variance in
anxiety (F= 5.38, P=0.005).
The generalpopulation risk ofdeveloping breast cancer In all,
47 (47.5%) of the tamoxifen trial participants recognised the
general population risk of developing breast cancer to be 1 in
12. Significantly fewer women from the screening programme
were accurate: 24 (27.6%) NBSP women with a history and
20 (23.3%) NBSP women without a history recognised that
all women have a 1 in 12 chance of developing breast cancer
in their lifetime (chi-square test = 8.07, P = 0.004). In total
there were 91 (33.5%) women aware of the general
population risk.
Table I Anxiety scores in relation to awareness of population risk of breast cancer in women
participating in the tamoxifen prevention trial compared with women with and without a family
history of breast cancer undergoing routine screening
Tamoxifen trial Screening women Screening women
participants with family history without family history
Number ofassessable women 99 87 86
General population risk
Aware
Mean anxiety score 37.5 (s.d. 9.8) 45.5 (s.d. 9.5) 39.3 (s.d. 10.2)
Number 47 24 20
Unaware
Mean anxiety score 36.8 (s.d. 8.8) 38.3 (s.d. 10.9) 39.5 (s.d. 9.8)
Number 52 63 66
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There was an interaction effect on anxiety between
understanding of general population risk and the three
experimental groups (trial participants, NBSP women with a
history and NBSP women without a history) (F=3.17,
P=0.01). That is to say only in the 91 women who were
aware of general population risk did anxiety scores vary
significantly in the three groups (F=5.43, P=0.006). Among
these 91 accurate women, NBSP women with a family history
had significantly higher anxiety scores than women partici-
pating in the tamoxifen trial (t=3.35, P=0.002) or NBSP
women without a family history (t=2.08, P=0.04). Women
participating in the tamoxifen trial had similar anxiety scores
to NBSP women without a family history (Table I).
Understanding of the herditary nature ofbreast cancer Two-
way analysis of variance revealed no relationship between
understanding of the hereditary nature of breast cancer and
experimental group on anxiety.
Discx~
Understanding of general population risk only accounted for
3% of the variance in anxiety found in the entire sample.
This was not unexpected as the relationship found between
risk perception and anxiety in this study was related to both
risk status' and 'clinic attended'. Therefore the relationship
existed only in a small group of the entire study population
and did not account for a large percentage of total variance.
A total of 91 (33.5%) of the entire sample of 272 women
correctly understood the general population risk of develop-
ing breast cancer to be 1 in 12 (Table I). Almost half, 47 of
99 (47.5%) of the women participating in the tamoxifen trial
were aware of this figure in comparison with 45 of 173 (26%)
of the NBSP women with or without a family history. This
suggests that the genetic counselling offered at the family
history clinic did improve understanding and is compatible
with other studies of population risk perceptions in 'at risk'
women attending a family history clinic. (Evans et al., 1993).
Fallowfield et al. (1990) found that only 14% of women
attending for routine screening at the same NBSP centre had
realistic risk perceptions. It would seem that there has been
some improvement in understanding of breast cancer risk in
women attending for routine screening during the past 5
years.
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Amongst the 91 accurate women, the 24 with a family
history not attending a specialist clinic had significantly
higher anxiety scores than the 47 with a history participating
in the tamoxifen trial (Table I). This is despite the less
stringent criteria of family history used as a definition of
'high risk' for women from the NBSP. These data do not add
support to the hypothesis that specialist clinics see a self-
selected group of the most anxious. Women participating in
the tamoxifen trial had similar anxiety scores to women
without a family history attending for routine screening. This
was true for women with accurate or inaccurate risk
perceptions.
One explanation of the findings is that women with
accurate risk perceptions who are highly anxious avoid
specialist clinics. Alternatively, participation in the prevention
programme or attendance at a specialist clinic may alleviate
anxiety in 'high risk' women with accurate risk perceptions.
Kash et al. (1992) and Lerman and Croyle, (1994) reported
high levels of anxiety in American women attending a breast
cancer family history clinic but not participating in any
prevention programme which suggests it may be participation
in the prevention programme rather than attendance at a
clinic which is related to any alleviation of anxiety. However,
there are no data from American 'at risk' women not
attending any specialist clinic; they too may have higher
levels of anxiety than those reported in American woman
attending a history clinic.
The data reported in our study suggest that participation
in the tamoxifen prevention programme, which requires
regular screening and attendance at a family history clinic
does not exacerbate anxiety and may even alleviate anxiety
for some women.
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